Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis

T P Doyle1, J E Loyd, I M Robbins

  • 1Division of Pediatric Cardiology and Center for Lung Research, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.

Insights

Mediastinal fibrosis, a complication of Histoplasma capsulatum infection, can obstruct pulmonary vessels. Percutaneously placed intravascular stents offer a new, effective treatment for this rare condition.

Area of Science:

  • Cardiology
  • Pulmonology
  • Infectious Diseases

Background:

  • Mediastinal fibrosis, a rare complication of Histoplasma capsulatum infection, can cause severe obstruction of pulmonary arteries, veins, and bronchi.
  • Current medical and surgical treatments for mediastinal fibrosis have shown limited efficacy.

Observation:

  • Four severely limited patients (WHO functional class III or IV) with mediastinal fibrosis underwent percutaneous intravascular stent placement.
  • Stents were placed in pulmonary arteries, veins, or both to alleviate vascular obstruction.

Findings:

  • All patients experienced immediate hemodynamic and clinical improvement following stent placement.
  • Three patients demonstrated sustained improvement in exercise tolerance for up to 4.5 years.
  • A single, self-limited pulmonary hemorrhage occurred as the only complication.

Implications:

  • Percutaneous stent placement represents a promising new treatment modality for central pulmonary vascular obstruction caused by mediastinal fibrosis.
  • This minimally invasive approach offers significant clinical benefit for patients with limited treatment options.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...